



如何利用相關資源選擇 適當的期刊投稿

Date: Sept 27, 2023

By Jade Li, 李麗娟, Customer Consultant, A&G, Elsevier

今日大綱



- 掠奪性期刊的崛起
- 如何尋找適當的期刊投稿
- 如何評估期刊
- Elsevier OA方案介紹




掠夺性期刊的崛起

Stand: 19.07.2018 06:00 Uhr

More than 5,000 German scientists have published papers in pseudo-scientific journals

Source: https://www.ndr.de/der_ndr/presse/More-than-5000-German-scientists-have-published-papers-in-pseudo-scientific-journals,fakescience178.html

掠奪性期刊的崛起



OPEN  ACCESS

掠奪性期刊的警告訊號 <prioritize self-interest>

假的或誤導資訊

假的期刊指標, 不正確的住址, 不正確的編輯委員會, 協會資訊, 以及誤導的同儕審核資訊.

編輯與出版實務上的偏差

看起來非專業的網站介面 – 充滿拼字或文法上的錯誤或不相關的內容資訊 – 為示警訊號.

資訊不透明

沒有任何資料顯示編輯決策是如何完成的, 收費的用途, 同儕審核過程如何進行, 無聯繫資訊, 無任何文章處理費的細節. 無法核查編輯和編輯委員會委員的資訊.

積極任意的邀稿

積極任意的邀稿如重複的電子郵件邀約 (警示訊號: 受邀者非該期刊領域)

掠奪性期刊的危害

科學

- 研究的決策是必須建立在可信賴的資料
- 掠奪性期刊為獲取利益，放棄了科學的出版原則
- 發表在掠奪性期刊上的文章未經核實，而被認為是不科學的

研究者或研究機構

- 金錢成本
- 聲譽成本
- 研究評估與排名上的不良影響
- 文獻的持久性
- 期刊不被收錄
- 可能的法律後續效應

掠奪性期刊檢查清單

- 閱讀該期刊過往文獻.
- 查看編輯委員會
- 查看是否是著名組織會員如DOAJ, COPE等等
- 檢查聯繫資訊
- 了解同儕審核過程
- 將整個期刊網站檢查過




<https://thinkchecksubmit.org/journals/>



如何尋找適當的期刊投稿

期刊與文獻的生態系統 -Elsevier 如何支持學術傳遞



如何尋找適當的期刊



- 同事或同儕
- 長官, 導師, 或作者
- 圖書館



- 引用的文章
- 重要文獻
- 重要作者



- 文獻種類
- OA文章
- 單一或多領域
- 特定出版社
- 研究數據發表



- DOAJ
- Enago OA Journal Finder
- Scopus, WOS
- ScienceDirect

如何尋找適當的期刊 – 以ScienceDirect為例

Publication title

- Food Chemistry (953)
- Biomedicine & Pharmacotherapy (928)
- Nutrition, Metabolism and Cardiovascular Diseases (889)
- Science of The Total Environment (872)
- Heliyon (856)
- Environmental Research (696)
- Journal of Ethnopharmacology (669)
- International Journal of Cardiology (582)
- Life Sciences (541)
- Food Research International (517)
- LWT (511)
- International Journal of Biological Macromolecules (510)
- The American Journal of Cardiology (481)
- Atherosclerosis (478)

Find articles with these terms

"cardiovascular disease"



Advanced search

Download selected articles [Export](#)

Review article ● *Open access*

1 **Chronic rheumatologic disorders and cardiovascular disease risk in women**

American Heart Journal Plus: Cardiology Research and Practice, 9 February 2023

Puja K. Mehta, Rebecca D. Levit, ... Carl J. Pepine

[View PDF](#) [Abstract](#) [Figures](#) [Export](#)

Review article ● *Full text access*

2 **Eliminating Disparities in Cardiovascular Disease for Black Women: JACC Review Topic of the Week**

Journal of the American College of Cardiology, 24 October 2022

Modele O. Ogunniyi, Zainab Mahmoud, ... Sharonne N. Hayes

[View PDF](#) [Abstract](#) [Graphical Abstract](#) [Figures](#) [Export](#)

透過主題領域找期刊– 以ScienceDirect為例



ScienceDirect®

Journals & Books

Showing 89 journals

Refine publications by

Domain

Medicine and Dentistry



Subdomain

Cardiology and Cardiovascu



Publication type

Journals

Journal status

Accepts submissions

A

[American Heart Journal](#)

Journal • Contains *open access*

[American Heart Journal Plus: Cardiology Research and Practice](#)

Journal • *Open access*

[The American Journal of Cardiology](#)

Journal • Contains *open access*

[The American Journal of the Medical Sciences](#)

Journal • Contains *open access*

[The American Journal of Pathology](#)

Journal • Contains *open access*

[American Journal of Preventive Cardiology](#)

Journal • *Open access*

[Annales de Cardiologie et d'Angéiologie](#)

Journal

ScienceDirect®


透過主題領域找期刊- 以Scopus為例

Scopus 內容

內容範圍指南 


Scopus 來源出版物清單 

書名清單 

Scopus 已終止的來源出版物清單 

在找免費的期刊排名和計量方式嗎?

Scopus 向非訂閱者提供免費統計數據。
查看期刊排行 >



學科領域



輸入學科領域

學科領域: Medicine x Cardiology And Cardiovascular Medicine x

來源出版物名稱 ↓		CiteScore ↓	最高百分比 ↓	引用次數 2019-22 ↓	文獻 2019-22 ↓	引用 % ↓	>
<input type="checkbox"/>	1 Ca-A Cancer Journal for Clinicians ICate	642.9	99% 1/366 Oncology	69,429	108	94	
<input checked="" type="checkbox"/>	2 New England Journal of Medicine ICate 	134.4	99% 1/830 General Medicine	310,795	2,313	85	
<input type="checkbox"/>	3 The Lancet ICate 	133.2	99% 2/830 General Medicine	240,101	1,803	74	
<input type="checkbox"/>	4 Nature Reviews Cancer ICate 	96.7	99% 1/214 Cancer Research	21,183	219	90	

如何尋找適當的期刊 – Elsevier Journal Finder

Find the right journal for your research

Looking for the best journal match for your paper?

Search the world's leading source of academic journals using your abstract or your keywords and other details.

> [More on how it works](#)

Match my abstract Search by keywords, aims & scope, journal title, etc...

Enter your abstract

Find journals >

Please enter abstract

Maximum 5,000 characters ⓘ

[Check if you're eligible](#) for open access (OA) savings.

Match my abstract Search by keywords, aims & scope, journal title, etc...

Background and Aims

Maximum 5,000 characters ⓘ

Find journals

Publication type ⓘ

OA Journals that offer gold OA

Journals with subscription

CiteScore ⓘ

All journals



Time to 1st decision ⓘ

All journals



Impact factor ⓘ

All journals



Time to publication ⓘ

All journals



Showing 39 journals matching your paper

Sort by: Best match ▾

Atherosclerosis ↗

Save journal

Submit paper >

ISSN: 0021-9150



Text match score



CiteScore

9.5

Impact Factor

5.3

Acceptance rate

17%

Time to 1st decision

3 weeks

Time to publication

6 weeks

Publishing options for this journal

Open Access

\$3,750

Article Publishing Charge (APC), excluding taxes

Your article will be made [publicly available](#) upon publication

Subscription

No publishing charge

Your article can be shared according to this journal's [article sharing policy](#)

Subject area

Cardiology and Cardiovascular Medicine

[Read more on this journal](#)



如何評估期刊

如何評估期刊



- 該手稿是否適合收錄在該期刊？
- 是否有任何贊助者/機構授權需考量？
- 是否該期刊在您想接觸的研究社群是可見的？
- 是否有合理的接受率？
- 是否該期刊有收錄在相關的資料庫？
- 期刊指標揭露了甚麼？
- 是否該期刊有信譽？



Atherosclerosis

Supports *open access*

9.5
CiteScore

5.3
Impact Factor

[Articles & Issues](#) ▾

[About](#) ▾

[Publish](#) ▾

[Order journal](#) ▾



[Search in this journal](#)

[Submit your article](#) ↗

[Guide for authors](#) ↗

[Latest issue](#)

[All issues](#)

[Articles in press](#)

[Special issues and article collections](#)

[Linked datasets](#)

[Sign in to set up alerts](#)

[RSS](#)

[Aims and scope](#)

[Editorial board](#)

[Journal insights](#)

[Abstracting & indexing](#)

[Abstracting and indexing](#)

About the journal

International Journal for Research and Investigation on Atherosclerosis and Related Diseases
Official Journal of the [European Atherosclerosis Society](#).

Atherosclerosis brings together, from all sources, papers concerned with investigation on **atherosclerosis**, its risk factors and clinical manifestations. *Atherosclerosis* covers basic and translational, clinical and population research approaches to **arterial** and **vascular biology** and **disease**, as well ...

Editor-in-Chief

Arnold von Eckardstein

University Hospital Zurich, Zurich, Switzerland

Publishing timeline

2.9 weeks	5.2 weeks	1.4 weeks
Time to First Decision	Review Time	Publication Time

- Embase
- PubMed/Medline
- BIOSIS Citation Index
- Chemical Abstracts

- Scopus
- Science Citation Index
- Science Citation Index Expanded



Atherosclerosis

Supports *open access*

9.5

CiteScore

5.3

Impact Factor

[Articles & Issues](#) ▾

[About](#) ▾

[Publish](#) ▾

[Order journal](#) ▾



[Search in this journal](#)

[Submit your article](#) ↗

[Guide for authors](#) ↗

[Submit your article](#)

[Guide for Authors](#)

[Open Access options](#)

[Language Editing services](#)

[Author Services](#)

Guide for Authors



[Download Guide for Authors in PDF](#)

Aims and scope +

INTRODUCTION

- Types of paper
- Contact information

BEFORE YOU BEGIN

- Submission declaration

- Peer review

REVISED SUBMISSIONS

- Essential title page information
- Abstracts

- Data visualization

- Research data

- Submission Checklist

- Changes to authorship

- Copyright



Atherosclerosis

Supports *open access*

9.5

CiteScore

5.3

Impact Factor

Articles & Issues ▾

About ▾

Publish ▾

Order journal ▾



Search in this journal

Submit your article ↗

Guide for authors ↗

Articles

Latest published

Articles in press

Top cited

Most downloaded

Most popular

Research article ● Full text access

Improving detection of obstructive coronary artery disease with an artificial intelligence-enabled electrocardiogram algorithm

Yin-Hao Lee, ... Po-Hsun Huang

September 2023



View PDF

Research article ● Open access

Bivariate relation of vascular health and blood pressure progression during childhood

Christoph Hauser, ... Henner Hanssen

September 2023



View PDF

Research article ● Full text access

Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis

Harpreet S. Bhatia, ... Sotirios Tsimikas

September 2023




View PDF

如何評估期刊 – 期刊指標

CiteScore

CiteScore 2021 計算方法

CiteScore 2021 計算在 2018-2021 發表的論文、回顧文獻、會議論文、專書論文、和數據論文等等在 2018-2021 所收到的引用總數，除以發表於 2018-2021 的出版物總數。



Journal Impact Factor

$$\frac{\text{Citation 2021}}{\text{Publication 2019 + 2020}} = \text{IF 2021}$$

“The impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.”

如何評估期刊 – 期刊指標

Atherosclerosis

Formerly known as: [Journal of atherosclerosis research](#)

Scopus coverage years: from 1970 to Present

Publisher: Elsevier

ISSN: 0021-9150 E-ISSN: 1879-1484

SJR

SCImago Journal Rank SJR 全名為 SCImago Journal Rank，是由 SCImago 研究團隊來自西班牙國家研究機構的 Félix de Moya 教授等三位所提出，其核心概念來自 Google 的 PageRank 演算法，根據引用權衡表以及複雜且性質不同的引用網絡資源如 Scopus 使用的特徵向量中心性來決定學術期刊的排名。SJR 指標是不受大小影響的計量方法，旨在衡量期刊目前的「文章平均聲望」

CiteScore 2022

9.5

SJR 2022

1.375

SNIP 2022

1.370



Source Normalized Impact per Paper

全名為 Source Normalized Impact per Paper (標準化影響係數) 由荷蘭萊頓大學CWTS團隊 Henk Moed 教授所提出，是根據某個主題領域的總引用次數、給予引用權重，進而衡量上下文引用所造成的影響。這個方法就是找出每篇論文中期刊引用的數目與主題領域內引用的可能性之間的比例。其目的在允許直接比較不同主題領域內的資料來源。可以突破傳統 Impact Factor 無法考量不同研究領域的引用情形。



Elsevier OA方案介紹



ELSEVIER

支持 開放取用

150k+

open access articles published

In 2022, Elsevier published 150,000 open access articles — a year-on-year increase of over 26%.

700+

gold open access journals

In 2022, we launched 88 new journals of which 93% were gold open access, growing the Elsevier portfolio to over 700 gold open access journals.

20m+

documents tagged
“open access”

We make it easy to find open access articles. Through our partnership with Impact story, over 20 million documents are tagged gold, hybrid, bronze or green open access in Scopus.

~2.8k

journals that enable
open access

As one of the fastest-growing open access publishers in the world, we enable nearly all of our 2,800+ journals to offer open access publishing.

注意事項

- 文章必須於2023年1月1日以後(含當日)被接受
- 通訊作者Corresponding author是指於投稿到發表整個流程與Elsevier聯繫的唯一通訊作者
- 通訊作者必須隸屬於參加該OA方案的機構
- 合格Eligible核心複合期刊 與純金色開放取用期刊請參考期刊查詢網頁
- 凡文章刊登於本合約未包含之期刊，不含折扣之APC將依上述連結向通訊作者開立發票。

合格期刊查詢網站

<https://reurl.cc/GXyy4v>

Find a participating journal in this agreement by title or by subject area:

Journal title

Subject area

All subjects

Search

Elsevier and CONCERT Consortium have established an agreement to support authors in Taiwan who wish to publish open access.

When publishing in eligible journals

If you are not sure which journal to use, you can search for journals using [JournalFinder](#).

[Gastroenterology](#) ↗

ISSN: 0016-5085

Primary Subject:

Gastroenterology and
Hepatology

OA Type:

Hybrid

通訊作者於文章接受後會收到電子郵件內連結告知須完成作者流程並選擇發表出版選項

作者點選 'Complete the Rights and Access information form 完成權利與存取表格'



Corresponding author
E-mail address
Journal
Article number
Our reference
PII

Welcome [redacted]
To help us finalize the publication of your article please complete the publishing form(s) below.
Note: you will receive a confirmation e-mail after completing each form.

Information you may need to provide to complete the forms

Rights and Access

[Complete the rights and access form >](#)

Help and Support

[How you can share your article](#)
[Author rights information](#)
[A guide to publishing Open Access](#)

Rights and Access



Corresponding author
E-mail address
Journal
Article number
Our reference
PII

Corresponding Author's Organization ⓘ

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

Organization name*

University

University of Taipei

Taipei, TW

Taipei, TW

Taipei, TW

National Tai

Taipei, TW


National

Taipei, TW

Taipei C

Save and Continue >

通訊作者選擇其所屬機構
資訊, 用以確認該作者並
與CONCERT合約媒合



Were there any co-authors for this article?

Yes

No

Add Co-author Details ⓘ

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial*	Last name*	
<input type="text" value="John"/>	<input type="text" value="Head"/>	
Organization name*	<input type="text" value="KU Leuven"/>	
Or use recently selected organization	<input type="text" value=""/>	

[+ Add another co-author](#)

通訊作者加入共同作者的
所屬機構細節資訊



作者可加入資助者細節。資助者可以是所屬機構或是不同機構。以此為例，Milliman, 美國是資助者

[Redacted content]

Did the research in this article receive funding?

Yes
 No

Funder Details ⓘ

Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.

For tips on searching for an organization please visit our [Support Center](#)

Organization name* 🗑️
Milliman Inc

Grant/Contract numbers* 🗑️
GT123

[+ Add grant/contract number](#)

[+ Add another organization](#)

Previous

Save and Continue >

- 根據通訊作者所屬機構細節，該作者可看到發表出版選項。首先是訂閱型，接著是金色開放取用選項。舉例來說，經過確認，作者收到10%的APC折扣。
- 如果會員機構館員在Elsevier平台拒絕作者請求，我們將明示作者會收到APC全額的發票但同時顯示可更改到訂閱型的選項。
- 作者選擇金色開放取用

Subscription

Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of Elsevier's programs >.

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article sharing rights outlined here >.

Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with Universitat de València upon validation, I will receive a 10% discount on the APC as part of the agreement between the CONCERT consortium and Elsevier >.

I will receive an invoice to pay the remainder of the APC.

I and others can share and reuse my article in the ways described by the user license I select.


Article Publishing Charge (APC)

	Price
	USD 4,050.00
	Institutional Agreement Discount
	- 405.00
<hr/>	
	To pay (on validation)
	(Excluding taxes)
	USD 3,645.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact Researcher Support to publish free of charge under the Subscription model.



Rights and Access



Review Order of this Article's publication using a mandated license

Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

 CC BY-NC-ND 4.0

A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.

[Read more about CC BY-NC-ND 4.0](#)


 CC BY 4.0

A license to permit readers to share and adapt your article for any purpose, even commercially.

[Read more about CC BY 4.0](#)

[Previous](#)[Save and Continue >](#)

- 系統顯示作者CC授權選項
- 作者選擇CC BY NC ND授權



作者選擇權利資訊

How best do you describe your organization's ownership structure?

Elsevier B.V.

Select Your Status

- I am the sole author of the manuscript
- I am one author signing on behalf of all co-authors of the manuscript

Please indicate which of the below applies to you:

- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
- I am a US Government employee but some of my co-authors are not
- I am not a US Government employee but some of my co-authors are
- The work was performed by contractors of the US Government under contract number:

Contract Number*

- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
- Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
- None of the above
- I am signing as an authorized representative and on behalf of my employer

Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.


- I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)*

E-mail address*

Previous

Save and Continue >



Elsevier B.V.

Elsevier B.V.

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights

I hereby grant to Elsevier B.V. an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

系統顯示作者與期刊授權出版
合約

For further information see the publishing ethics page at <https://www.elsevier.com/about/our-business/policies/publishing-ethics> and the journal home page. For further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions>

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of International Federation of Automatic Control ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright>.

I have read and agree to the terms of the License Agreement.

17 December 2021

T-copyright license-v5/2017

Previous

Accept Agreement >

作者同意期刊授權出版合約

1

Corresponding
Author

2

Co-Author

3

Research
Funders

4

Publishing
Options

5

Licenses

6

Rights

7

Publishing
Agreement

8


Payment
Details


9

Review Order

10

Confirmation



 The invoice address you provide will be visible to the institution approving your eligibility for the discount

Invoice address



Invoice an Organization



Invoice an Individual

Select organization from list *

Search for different organization

作者選擇寄發票給個人, 或機構(如適用)

Total payment due

Price (excluding taxes)

USD 4,050.00

Institutional Agreement Discount



- 405.00

Tax

+ 0.00

 Tax amounts are indicative and will be confirmed on the invoice

To pay

Total price (including taxes)



USD 3,645.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

Previous

Save and Continue >

1

Corresponding Author

2

Co-Author

3

Research Funders

4

Publishing Options

5

Licenses

6

Rights

7

Publishing Agreement

8

Payment Details

9

Review Order

10

Confirmation



The invoice address you provide will be visible to the institution approving your eligibility for the discount

Invoice address

Invoice an Organization (selected) / Invoice an Individual

Select organization from list * University

Country or Region * Taiwan

Address Line 1 *

Address Line 2

City * 台北市

State

Zip/Post Code *

Title * Mr

作者選擇寄送發票到個人或機構帳單地址(如適用)

Total payment due

Price (excluding taxes)
USD 4,050.00

Institutional Agreement Discount
- 405.00

Tax
0.00

Tax amounts are indicative and will be confirmed on the invoice

To pay

Total price (including taxes)
USD 3,645.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

作者可以增加 VAT 加
值稅號, 免稅資訊(如適
用). 採購訂號碼是必要
的.

Zip/Post Code*

Title*

Mr

First name

John

Surname*

Head

E-mail*

Johnhead@university.edu

Phone number (including country code)*

+88

Purchase order number*

GT123

VAT/GST/CST Registration Number: ⓘ

Does the organization have a VAT / GST / CST registration number?

- No the organization does not have a VAT / GST / CST registration number
 Yes the organization does have a VAT / GST / CST registration number

Payment

How do you want to pay for the Article Publishing Charge? * ⓘ

- Credit / Debit card
 Send an invoice

An invoice will be emailed to the address you have entered. Payment can be made via Bank Transfer, Credit Card, or via telephone.

Previous

Total payment due

Price (excluding taxes)

USD 4,050.00

Institutional Agreement Discount



- 405.00

Tax

+ 0.00

ⓘ Tax amounts are indicative and will be confirmed on the invoice

To pay

Total price (including taxes)

USD 3,645.00



If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

Save and Continue >

當作者點選訂單與付款：

- 通訊作者與共同作者會透過電子郵件收到該摘要內容
- 文章會在24小時內在 ScienceDirect 上變成開放取用
- 館員將會在48小時內收到查驗通知，將有3個禮拜確認該請求。
- 如果圖書館員核准此請求，作者會收到折扣後的發票。
- 如果圖書館員拒絕此請求，作者會收到全額發票。

Review Order

Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access *
User License	CC BY-NC-ND 4.0
Publishing Agreement	<ul style="list-style-type: none">I am one author signing on behalf of all co-authors of the manuscript <p>I may share my final published article widely in accordance with the user License that I have selected. Further details on Elsevier Sharing Policy here.</p>

Purchase order number
GT123

Invoice Address
Mr John Head
University
J
台北市
Taiwan
10659
Phone: +886
E-mail: john

Invoiced by: Elsevier B.V.

By clicking on Order and Pay below, you
1) Acknowledge that we will immediately start providing the service to you. Upon full performance of the service you acknowledge that you will lose your right to cancel and
2) Understand that the order is subject to the Terms and Conditions of Purchase and Sale and agree to be bound to all of its terms as specified in [Terms and Conditions of Purchase and Sale](#).

11 December 2022

Total payment due

Price (excluding taxes)	USD 4,050.00
Institutional Agreement Discount	- 405.00
Tax	+ 0.00
Total price (including taxes)	USD 3,645.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Previous](#) [Order and Pay >](#)

作者支援服務

- 作者投稿相關問題 – support@elsevier.com
- Author journey 作者流程影片:
https://service.elsevier.com/app/answers/detail/a_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP_X/
- Elsevier Author Hub 作者中心
<https://www.elsevier.com/authors>
- Elsevier 作者流程簡報 (KMU網站)
https://olis.kmu.edu.tw/images/Elsevier_CONCERT_discount_author_journey_CH_20230103.pdf

參考網站

- Elsevier 官網 – <https://www.Elsevier.com/en-xs>
- ScienceDirect 網站 - <https://www.sciencedirect.com/>
- Scopus 網站 - <https://www.scopus.com>
- Elsevier Journal Finder - <https://journalfinder.elsevier.com/>
- Elsevier Researcher Academy - <https://researcheracademy.elsevier.com/>